Publikationen (Auswahl)
K. J. Legscha, E. Antunes Ferreira, A. Chamoun, A. Lang, M. H. S. Awwad, G. N. H. Q. Ton, D. Galetzka, B. Guezguez, M. Hundemer, J.-C. Bourdon, M. Munder,
M. Theobald, H. Echchannaoui. Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.
J Immunother Cancer. 2021 Jun;9(6):e001846.
doi: 10.1136/jitc-2020-001846.
V. Vonwirth, Y. Bülbül, A. Werner, H. Echchannaoui, J. Windschmitt, A. Habermeier, S. Ioannidis, N. Shin, R. Conradi, M. Bros, S. Tenzer,
M. Theobald, EI Closs, M. Munder. Inhibition of arginase 1 liberates potent T cell immunostimulatory activity of human neutrophil granulocytes.
Front Immunol. 2021. Feb 26.
doi: 10.3389/fimmu.2020.617699.
M. M. Dzama, M. Steiner, J. Rausch, D. Sasca, J. Schönfeld, K. Kunz, M. C. Taubert, G. M. McGeehan, C. W. Chen, A. Mupo, P. Hähnel,
M. Theobald, T. Kindler, R. P. Koche, G. S. Vassiliou, S. A. Armstrong, M. W. M. Kühn. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Blood. 2020; 136(21): 2442-2456.
P. Woelfinger, K. Epp, L. Schaefer, D. Kriege, M. Theobald, T. Bopp, E. M. Wagner-Drouet. CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen. Br J Haematol. 2020; 191(2): 253-262.
K. N. Kropp, T. J. Schäufele, M. Fatho, M. Volkmar, R. Conradi,
M. Theobald, T. Wölfel, C. A. Wölfel. bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences.
PLoS One. 2020;15(9):e0238875.
G. Hess, K. Wagner, U. Keller, P. La Rosee, J. Atta, K. Hübel, C. Lerchenmueller, D. Schoendube, M. Witzens-Harig, C. Ruckes, C. Medler, C. van Oordt, W. Klapper,
M. Theobald, M. Dreyling. Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.
Hemasphere. 2020; 4(3): e398.
D. Sasca, J. Szybinski, A. Schüler, V. Shah, J. Heidelberger, P. S.Haehnel, A. Dolnik, O. Kriege, E. M. Fehr, W. H. Gebhardt, G. Reid, C. Scholl, M. Theobald, L. Bullinger, P. Beli, T. Kindler. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. Blood. 2019; 133(21): 2305-2319.
H. Echchannaoui, J. Petschenka, E. A. Ferreira, B. Hauptrock, C. Lotz-Jenne, R. H. Voss,
M. Theobald. A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo.
Mol Ther. 2019; 27(1): 261-271.
A. Werner, D. Pieh, H. Echchannaoui, J. Rupp, K. Rajalingam,
M. Theobald, E. I. Closs, M. Munder. Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability.
Front Oncol. 2019; 9: 1268.
G. van Gorkom, M. van Gelder, D. J. Eikema, H. J. Blok, M. T. van Lint, Y. Koc, F. Ciceri, D. Beelen, P. Chevallier, D. Selleslag, D. Blaise, R. Foá, P. Corradini, L. Castagna, C. Moreno, C. Solano, L. P. Müller, J. Tischer, I. Hilgendorf, M. Hallek, J. Bittenbring,
M. Theobald, J. Schetelig, N. Kröger; CLL subcommittee; Chronic Malignancies Working Party of the EBMT. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
Bone Marrow Transplant. 2018; 53(3): 255-263.
M. L. Hütter-Krönke, A. Benner, K. Döhner, J. Krauter, D. Weber, M. Moessner, C. H. Köhne, H. A. Horst, I. G. Schmidt-Wolf, M. Rummel, K. Götze, E. Koller, A. L. Petzer, H. Salwender, W. Fiedler, H. Kirchen, D. Haase, S. Kremers, M.
Theobald, A. C. Matzdorff, A. Ganser, H. Döhner, R. F. Schlenk. Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.
Haematologica. 2016; 101(7): 839-845.
D. Knies, S. Klobuch, S. A. Xue, M. Birtel, H. Echchannaoui, O. Yildiz, T. Omokoko, P. Guillaume, P. Romero, H. Stauss, U. Sahin, W. Herr, M. Theobald, S. Thomas, R. H. Voss. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget. 2016; 7(16): 21199-2221.
E. Distler, J. Albrecht, A. Brunk, S. Khan, E. Schnürer, M. Frey, A. Mottok, A. L. Jordán-Garrote, C. Brede, A. Beilhack, A. Mades, D. Tomsitz,
M. Theobald, W. Herr, U. F. Hartwig. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Int J Cancer. 2016; 138(5): 1256-68.
J. Versluis, C. L. Hazenberg, J. R. Passweg, W. L. van Putten, J. Maertens, B. J. Biemond,
M. Theobald, C. Graux, J. Kuball, H. C. Schouten, T. Pabst, B. Löwenberg, G. Ossenkoppele, E. Vellenga, J. J. Cornelissen; HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Lancet Haematol. 2015; 2(10): e427-36.
D. Sasca, P. S. Hähnel, J. Szybinski, K. Khawaja, O. Kriege, S. V. Pante, L. Bullinger, S. Strand, D. Strand,
M. Theobald, T. Kindler. SIRT1 prevents genotoxic stress-induced p53 activation in acute myeloid leukemia.
Blood. 2014; 124(1): 121-33.
P. S. Hähnel, B. Enders, D. Sasca, W. P. Roos, B. Kaina, L. Bullinger,
M. Theobald, T. Kindler. Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.
Blood. 2014; 123(15): 2355-66.
S. Thomas, S. Klobuch, K. Besold, B. Plachter, J. Dörrie, N. Schaft,
M. Theobald, W. Herr. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.
Eur J Immunol. 2012;42(12):3442-53.
B. Lowenberg, T. Pabst, E. Vellenga, W. van Putten, H. C. Schouten, C. Graux, A. Ferrant, P. Sonneveld, B. J. Biemond, A. Gratwohl, G. E. de Greef, L. F. Verdonck, M. R. Schaafsma, M. Gregor,
M. Theobald, U. Schanz, J. Maertens, and G. J. Ossenkoppele: Cytarabine Dose for Acute Myeloid Leukemia.
N. Engl. J. Med. 2011, 364(11): 1027-1036.
E. Vellenga, W. van Putten, G. J. Ossenkoppele, L. F. Verdonck,
M. Theobald, J. J. Cornelissen, P. C. Huijgens, J. Maertens, A. Gratwohl, R. Schaafsma, U. Schanz, C. Graux, H. C. Schouten, A. Ferrant, M. Bargetzi, M. F. Fey, and B. Lowenberg: Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.
Blood 2011, 118(23): 6037-6042.
R. H. Voss, S. Thomas, C. Pfirschke, B. Hauptrock, S. Klobuch, J. Kuball, M. Grabowski, R. Engel, P. Guillaume, P. Romero, C. Huber, P. Beckhove, and
M. Theobald: Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells.
Blood 2010, 115(25): 5154-5163.
J. Kuball, B. Hauptrock, V. Malina, E. Antunes, R.-H. Voss, M. Wolfl, R. Strong,
M. Theobald, and P. D. Greenberg: Increasing functional avidity of TCR-redirected T cells by removing defined
N-glycosylation sites in the TCR constant domain.
J. Exp. Med. 2009, 206: 463-475.
R.-H. Voss, R. A. Willemsen, J. Kuball, M. Grabowski, R. Engel, R. S. Intan, P. Guillaume, P. Romero, C. Huber, and
M. Theobald: Molecular design of the Cαβ interface favors specific pairing of introduced TCRαβ in human T cells.
J. Immunol. 2008, 180: 391-401.
C. Lotz, S. Abdel Mutallib, N. Oehlrich, U. Liewer, E. Antunes Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, H. Goldschmidt, and
M. Theobald: Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
J. Immunol. 2005, 175: 1301-1309.
J. Kuball, F. W. Schmitz, R.-H. Voss, E. Antunes Ferreira, R. Engel, P. Guillaume, S. Strand, P. Romero, C. Huber, L. A. Sherman, and
M. Theobald: Cooperation of human tumor-reactive CD4
+ and CD8
+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Immunity 2005, 22: 117-129.
B. Löwenberg, W. van Putten,
M. Theobald, J. Gmür, L. Verdonck, P. Sonneveld, M. Fey, H. Schouten, G. de Greef, A. Ferrant, T. Kovacsovics, A. Gratwohl, S. Daenen, P. Huijgens, and M. Boogaerts, for the Dutch-Belgian Hemato-Oncology (HOVON) Cooperative Group and the Swiss Group for Clinical Cancer Research: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
N. Engl. J. Med. 2003, 349: 743-752.
T. Stanislawski, R.-H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. H. Bolhuis, C. J. Melief, C. Huber, H. J. Stauss, and
M. Theobald: Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Nature Immunol. 2001, 2: 962-970.
M. Theobald, T. Ruppert, U. Kuckelkorn, J. Hernandez, A. Häussler, E. Antunes Ferreira, U. Liewer, J. Biggs, A. J. Levine, C. Huber, U. H. Koszinowski, P.-M. Kloetzel, and L. A. Sherman: The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
J. Exp. Med. 1998, 188: 1017-1028.
M. Theobald, J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.
J. Exp. Med. 1997, 185: 833-841.
M. Theobald, J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman: Targeting p53 as a general tumor antigen.
Proc. Natl. Acad. Sci. U.S.A. 1995, 92: 11993-11997.
S. Chattopadhyay,
M. Theobald, J. Biggs, and L. A. Sherman: Conformational differences in major histocompatibility complex-peptide complexes can result in alloreactivity.
J. Exp. Med. 1994, 179: 213-219.
M. Theobald and D. Bunjes: Pretransplant detection of human minor histocompatibility antigen-specific naive and memory interleukin-2-secreting T cells within class I major histocompatibility complex (MHC)-restricted CD8+ and class II MHC-restricted CD4+ T cell subsets.
Blood 1993, 82: 298-306.
T. Nierle, D. Bunjes, R. Arnold, H. Heimpel, and
M. Theobald: Quantitative assessment of posttransplant host-specific interleukin-2-secreting T-helper cell precursors in patients with and without acute graft-versus-host disease after allogeneic HLA-identical sibling bone marrow transplantation.
Blood 1993, 81: 841-848.
M. Theobald, T. Nierle, D. Bunjes, R. Arnold, and H. Heimpel: Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings.
N. Engl. J. Med. 1992, 327:1613-1617.
